Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cancer Research

• Publication date

  2003-11-15

• Fields of study

  Medicine

• Identifiers
  PMID 14633713
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gene therapy for prostate cancer

  2004cited by this paper
• Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.

  2003cited by this paper
• Therapeutic targets for metastatic prostate cancer.

  2003cited by this paper
• Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk

  2002cited by this paper
• Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.

  2002cited by this paper
• Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.

  2002cited by this paper
• Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters

  2002cited by this paper
• Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report.

  2001cited by this paper
• Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer

  2001cited by this paper
• Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA1

  2001cited by this paper
• In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter.

  2001cited by this paper
• Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer.

  2001cited by this paper
• In situ gene therapy for prostate cancer: immunomodulatory approaches

  2001cited by this paper
• Prostate-Specific Antigen Response and Systemic T Cell Activation After In Situ Gene Therapy in Prostate Cancer Patients Failing Radiotherapy

  2001cited by this paper
• Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients1

  2001cited by this paper
• Interleukin 12 Gene Therapy of Cancer by Peritumoral Injection of Transduced Autologous Fibroblasts: Outcome of a Phase I Study

  2001cited by this paper
• Macrophages Transfected with Adenovirus to Express IL-4 Reduce Inflammation in Experimental Glomerulonephritis1

  2001cited by this paper
• Agranulocytosis and Hemolytic Anemia in Patients With Renal Cell Cancer Treated With Interleukin-12

  2001cited by this paper
• Gene transfer into inflamed glomeruli using macrophages transfected with adenovirus

  2000cited by this paper
• Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression.

  2000influential reference
• Cytopathic effect of in situ gene therapy in prostate cancer.

  2000cited by this paper
• Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system.

  2000cited by this paper
• Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial.

  2000cited by this paper
• Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells.

  2000cited by this paper
• Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

  2000cited by this paper
• Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

  2000cited by this paper
• Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression

  2000cited by this paper
• The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent1

  2000cited by this paper
• Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines.

  2000influential reference
• Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice.

  2000cited by this paper
• Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.

  2000cited by this paper
• The Toxicology of Interleukin-12: A Review

  1999cited by this paper
• In Situ Gene Therapy for Adenocarcinoma of the Prostate: A Phase I Clinical Trial

  1999cited by this paper
• Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.

  1999cited by this paper
• Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model

  1999influential reference
• Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

  1999cited by this paper
• A monoclonal antibody directed against the murine macrophage surface molecule F4/80 modulates natural immune response to Listeria monocytogenes.

  1999cited by this paper
• Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12.

  1999cited by this paper
• Infusion of dendritic cells pulsed with HLA‐A2‐specific prostate‐specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone‐refractory metastatic disease

  1999cited by this paper
• Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer

  1999cited by this paper
• Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice.

  1998cited by this paper
• Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.

  1998cited by this paper
• Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents.

  1998cited by this paper
• Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production

  1997cited by this paper
• Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

  1997cited by this paper
• Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

  1997cited by this paper
• Prostate Cancer Gene Therapy: Herpes Simplex Virus Thymidine Kinase Gene Transduction Followed by Ganciclovir in Mouse and Human Prostate Cancer Models

  1996cited by this paper
• Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-Lasting Immunity That Is Associated with Highly Localized Expression of Interleukin-12

  1996cited by this paper
• Methods for construction of adenovirus vectors

  1995cited by this paper
• Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer.

  1995cited by this paper
• Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization.

  1995cited by this paper
• Allelic loss in locally metastatic, multisampled prostate cancer.

  1994cited by this paper
• Demonstration of a rational strategy for human prostate cancer gene therapy.

  1994cited by this paper
• Intensity of class I antigen expression on human tumour cell lines and its relevance to the efficiency of non-MHC-restricted killing.

  1993cited by this paper
• Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12.

  1993cited by this paper
• F4/80, a monoclonal antibody directed specifically against the mouse macrophage

  1981cited by this paper

• Engineered macrophages in breast Cancer: bridging targeted therapy and advanced drug delivery.

  2025cites this paper
• Engineering macrophages for targeted immunotherapy and drug delivery in melanoma

  2025cites this paper
• Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy

  2024cites this paper
• Gene-based delivery of immune-activating cytokines for cancer treatment.

  2023cites this paper
• Engineering interferons and interleukins for cancer immunotherapy.

  2022cites this paper
• Cancer Immunotherapies Based on Genetically Engineered Macrophages.

  2022cites this paper
• The Roles of Tumor-Associated Macrophages in Prostate Cancer

  2022cites this paper
• Macrophage phenotype-switching in cancer.

  2022cites this paper
• Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy

  2022cites this paper
• Considering the potential for gene-based therapy in prostate cancer

  2021cites this paper
• Next-generation cytokines for cancer immunotherapy

  2021cites this paper
• М3 макрофаги останавливают деление клеток предстательной железы больного раком простаты

  2020cites this paper
• Localized Interleukin-12 for Cancer Immunotherapy

  2020cites this paper
• Macrophages as delivery vehicles for anticancer agents.

  2019cites this paper
• Stimulation of Glioblastoma Proliferation by Macrophages Through CD47/SIRPα

  2017cites this paper
• [Reprogrammed M1 macrophages with inhibited STAT3, STAT6 and/or SMAD3 extends lifespan of mice with experimental carcinoma].

  2017cites this paper
• Exploiting the cancer niche: Tumor‐associated macrophages and hypoxia as promising synergistic targets for nano‐based therapy

  2017cites this paper
• Yeast‐mediated mRNA delivery polarizes immuno‐suppressive macrophages towards an immuno‐stimulatory phenotype

  2017cites this paper
• 1, 25(OH)2D3-induced interaction of vitamin D receptor with p50 subunit of NF-κB suppresses the interaction between KLF5 and p50, contributing to inhibition of LPS-induced macrophage proliferation.

  2017cites this paper
• M3 Macrophages Stop Division of Tumor Cells In Vitro and Extend Survival of Mice with Ehrlich Ascites Carcinoma

  2017cites this paper
• Fonctions nucléaires du récepteur de CSF-1 dans les monocytes humains

  2017cites this paper
• Enhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesions.

  2016cites this paper
• Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3

  2016cites this paper
• Macrophage Polarisation: A collaboration of Differentiation, Activation and Pre-Programming?

  2015cites this paper
• Polymeric oncolytic adenovirus for cancer gene therapy.

  2015cites this paper
• Migration Stimulating Factor : new marker for tumour progression?

  2015cites this paper
• macrophages through transient early activation of monocytes Tumor-derived hyaluronan induces formation of immunosuppressive

  2014cites this paper
• Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases.

  2014cites this paper
• Physiological organization of immune response based on the homeostatic mechanism of matrix reprogramming: implication in tumor and biotechnology.

  2014cites this paper
• Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.

  2014cites this paper
• Trafficking of phagocytic peritoneal cells in hypoinsulinemic-hyperglycemic mice with systemic candidiasis

  2013cites this paper
• Kupffer cells suppress hepatocarcinogenesis and metastasis in tumor orthotopic implanted Kunming mice.

  2013cites this paper
• T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein

  2013cites this paper
• Role of Macrophage in Tumor Microenvironment: Prospect in Cancer Immunotherapy

  2013cites this paper
• Chapter six--Adenovirus-based immunotherapy of cancer: promises to keep.

  2012cites this paper
• Immunobiology of Monocytes/Macrophages in Hepatocellular Carcinoma

  2012cites this paper
• Macrophages in Tumor Microenvironments and the Progression of Tumors

  2012cites this paper
• Non-human Prostate Cancer Cell Lines

  2012cites this paper
• Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer

  2012cites this paper
• Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.

  2012cites this paper
• Cellular Vehicles for Cancer Gene Therapy

  2012cites this paper
• Chapter six--Adenovirus-based immunotherapy of cancer: promises to keep.

  2012cites this paper
• In vivo imaging of immune cell trafficking in cancer

  2011influential citation
• Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model

  2011cites this paper
• The PCa Tumor Microenvironment

  2011cites this paper
• Recent developments in prostate cancer biomarker research: therapeutic implications.

  2011cites this paper
• Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation

  2009cites this paper
• Tumor-associated macrophages: effectors of angiogenesis and tumor progression.

  2009cites this paper
• Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer

  2009cites this paper
• Gene-modified bone marrow cell therapy for prostate cancer

  2008cites this paper
• Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages

  2008cites this paper
• Inflammation and prostate cancer: a future target for prevention and therapy?

  2008cites this paper
• Macrophages in tumour development and metastasis

  2008cites this paper
• TGFβ is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction

  2008cites this paper
• Chapter 56 – Gene Therapy and Oncolytic Viruses

  2008cites this paper
• Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes.

  2007cites this paper
• Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer

  2007cites this paper
• Radiation-Induced Immune Modulation in Prostate Cancer

  2007cites this paper
• Cytokine Gene Therapy for Genitourinary Cancer

  2007cites this paper
• Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer

  2007cites this paper
• Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors.

  2007cites this paper
• Macrophages and the hypoxic tumour microenvironment.

  2007cites this paper
• In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines.

  2007cites this paper
• Hepatocellular Carcinoma with Monocyte Chemoattractant Protein-1 Effects of Suicide Gene Therapy Combined Prolonged , NK Cell-Mediated Antitumor

  2006cites this paper
• Distinct role of macrophages in different tumor microenvironments.

  2006cites this paper
• Prolonged, NK Cell-Mediated Antitumor Effects of Suicide Gene Therapy Combined with Monocyte Chemoattractant Protein-1 against Hepatocellular Carcinoma

  2006cites this paper
• Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer

  2006cites this paper
• Using Genetically Engineered Mice to Probe the Role of Bioactive Lipids in Prostate Carcinogenesis

  2006cites this paper
• Gene therapy for prostate cancer: Current strategies and new cell‐based approaches

  2006cites this paper
• Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion.

  2006cites this paper
• Tetracycline-regulated intratumoral expression of interleukin-3 enhances the efficacy of radiation therapy for murine prostate cancer

  2006cites this paper
• Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer model

  2006cites this paper
• Soluble mediators of inflammation during tumor development.

  2005cites this paper
• Adenovirus as vehicle for anticancer genetic immunotherapy

  2005cites this paper
• Immune Cell Subsets Direct or Antagonize Tumor Immunity: Promotion of TH1 Responses in Tumor Vaccination

  2005cites this paper
• Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma.

  2004cites this paper
• Cellular vehicles for cancer gene therapy: current status and future potential.

  2004cites this paper